AKTS NASDAQ
Aktis Oncology, Inc.
1W: -1.9%
1M: -13.1%
3M: +1.2%
YTD: -14.6%
1Y: +15559.3%
3Y: +364.1%
5Y: +137.2%
$20.34
+1.22 (+6.38%)
After Hours: $22.35 (+2.01, +9.88%)
Weekly Expected Move ±8.9%
$16
$18
$20
$21
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (17)
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology to Present at the BofA Securities Health Care Conference
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
Aktis Oncology, Inc. reports FY results
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Aktis Oncology to Present at Upcoming March Investor Conferences
A Fresh IPO That Long-Term Investors Shouldn't Ignore
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO
Aktis Oncology prices upsized US IPO at $18 per share
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering